模拟肝细胞癌的肝血管肉瘤患者在肝移植前使用阿特唑单抗和贝伐单抗。

IF 2.7 4区 医学 Q3 IMMUNOLOGY
Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-03-14 DOI:10.1080/1750743X.2025.2478811
Siqi Qiu, Zhipeng Zong, Kang He
{"title":"模拟肝细胞癌的肝血管肉瘤患者在肝移植前使用阿特唑单抗和贝伐单抗。","authors":"Siqi Qiu, Zhipeng Zong, Kang He","doi":"10.1080/1750743X.2025.2478811","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatic angiosarcoma is a rare yet aggressive malignancy, which is prone to misdiagnosis due to the lack of specific molecular and radiological characteristics. The treatment regimens remain controversial and disappointing. Randomized clinical trials are limited due to the rarity of this specific aggressive malignancy. Independent case reports or series can provide relevant references for treatment. We reported the very first hepatic angiosarcoma received Atezolizumab and Bevacizumab as a first-line treatment prior to liver transplantation, which resulted in a partial pathological response under specific molecular mutations. This case illustrates the potential role of immune checkpoint inhibitor combined with anti-angiogenic therapy as an off-label treatment option warranting further investigation.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"175-178"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951687/pdf/","citationCount":"0","resultStr":"{\"title\":\"Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma.\",\"authors\":\"Siqi Qiu, Zhipeng Zong, Kang He\",\"doi\":\"10.1080/1750743X.2025.2478811\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hepatic angiosarcoma is a rare yet aggressive malignancy, which is prone to misdiagnosis due to the lack of specific molecular and radiological characteristics. The treatment regimens remain controversial and disappointing. Randomized clinical trials are limited due to the rarity of this specific aggressive malignancy. Independent case reports or series can provide relevant references for treatment. We reported the very first hepatic angiosarcoma received Atezolizumab and Bevacizumab as a first-line treatment prior to liver transplantation, which resulted in a partial pathological response under specific molecular mutations. This case illustrates the potential role of immune checkpoint inhibitor combined with anti-angiogenic therapy as an off-label treatment option warranting further investigation.</p>\",\"PeriodicalId\":13328,\"journal\":{\"name\":\"Immunotherapy\",\"volume\":\" \",\"pages\":\"175-178\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951687/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1750743X.2025.2478811\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2478811","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

摘要肝血管肉瘤是一种罕见但侵袭性的恶性肿瘤,由于缺乏特定的分子和放射学特征,容易被误诊。治疗方案仍然存在争议,令人失望。由于这种特殊的侵袭性恶性肿瘤的罕见性,随机临床试验受到限制。独立的病例报告或系列可以为治疗提供相关参考。我们报道了首例肝血管肉瘤在肝移植前接受Atezolizumab和Bevacizumab作为一线治疗,这导致了特定分子突变下的部分病理反应。该病例说明了免疫检查点抑制剂联合抗血管生成治疗作为标签外治疗选择的潜在作用,值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma.

Hepatic angiosarcoma is a rare yet aggressive malignancy, which is prone to misdiagnosis due to the lack of specific molecular and radiological characteristics. The treatment regimens remain controversial and disappointing. Randomized clinical trials are limited due to the rarity of this specific aggressive malignancy. Independent case reports or series can provide relevant references for treatment. We reported the very first hepatic angiosarcoma received Atezolizumab and Bevacizumab as a first-line treatment prior to liver transplantation, which resulted in a partial pathological response under specific molecular mutations. This case illustrates the potential role of immune checkpoint inhibitor combined with anti-angiogenic therapy as an off-label treatment option warranting further investigation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Immunotherapy
Immunotherapy 医学-免疫学
CiteScore
5.00
自引率
3.60%
发文量
113
审稿时长
6-12 weeks
期刊介绍: Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信